SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
AgeX Therapeutics, Inc. (AGE) .
本页证实的标准:
- VALUE (0/100, 未通过) — 综合估值评分低于60/100的通过门槛。
SharesGrow 综合评分： 22/100 其中 0/7 项标准通过。
SharesGrow 7-Criteria Score
~
健康
50/100
Debt-to-Equity & liquidity
→ Health
估值概览 — AGE
估值倍数
P/E (TTM)0.0
前瞻 P/EN/A
PEG 比率N/A
前瞻 PEGN/A
P/B 比率0.00
P/S 比率870.07
EV/EBITDA0.0
每股数据
EPS (TTM)$-1.91
每股账面价值$0.00
每股营收$0.01
每股自由现金流$0.00
收益率与内在价值
盈利收益率N/A
股息收益率0.00%
P/E Ratio & Earnings Yield
每股收益 (EPS) 历史
| Year |
EPS（稀释） |
营收 |
净利润 |
净利润率 |
| 2017 |
$-6.46 |
$1.4M |
$-6.58M |
-468.7% |
| 2018 |
$-7.56 |
$1.4M |
$-7.5M |
-537.4% |
| 2019 |
$-11.69 |
$1.73M |
$-12.38M |
-716.7% |
| 2020 |
$-10.25 |
$1.87M |
$-10.98M |
-587.6% |
| 2021 |
$-9.49 |
$144K |
$-10.22M |
-7097.2% |
| 2022 |
$-9.89 |
$34K |
$-10.67M |
-31394.1% |
| 2023 |
$-13.72 |
$142K |
$-14.8M |
-10424.6% |
| 2024 |
$-1.51 |
$56K |
$-11.14M |
-19894.6% |
| 2025 |
$-1.91 |
$130K |
$-19.44M |
-14950.8% |
